AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01130987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized handoff tool
Description: Computer program that facilitates accurate transmission of patient information between residents
Study NCT01130987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team training
Description: Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
Study NCT02225548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Study NCT01414348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel rehabilitation approach
Description: 1 hr, 2x/week for up to 15 sessions
Study NCT02149667 — intervention group
Intervention type: DEVICE
Intervention: total hip arthroplasty implant
Study NCT02225548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Study NCT03088865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: aspirating first blood volume into a regular blood collection tube
Description: order of blood drawing
Study NCT03088865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: aspirating first blood volume into a regular blood collection tube
Description: order of blood drawing
Study NCT03652142 — intervention group
Intervention type: OTHER
Intervention: Biomarker Research
Description: The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
Study NCT03652142 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
Study NCT03004378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Fitbit Alta
Study NCT00477165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 20mg/day for 4 weeks, then 40 mg/day for 4 weeks
Study NCT00477165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
Study NCT03343275 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lit control pHDown
Description: Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
Study NCT03343275 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Lit control pHDown
Description: Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
Study NCT03803332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Psychotherapy including imaginal and in vivo exposure for PTSD.
Study NCT03803332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
Study NCT01277094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral daily doses for 12 weeks
Study NCT01277094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: Oral daily doses for 12 weeks
Study NCT04506697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Description: The patient is given a portable uroflowmeter for performing uroflowmetry at home, and the NetHealth app is installed on his smartphone. The patient registers his account in the app. A personal uroflowmeter is paired with the patient's smartphone using the installed app via a Bluetooth connection. The investigator trains the patient how to use the app and how to conduct uroflowmetry at home. The patient within 1 day (24 hours) at home performs uroflowmetry during all urination, including night urination.
Study NCT02377375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-assisted technique
Description: Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
Study NCT02377375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: Medtronic DBS lead 3391-28cm
Study NCT03123497 — intervention group
Intervention type: OTHER
Intervention: completion of questionnaire
Description: completion of questionnaire for patient and parent
Study NCT01564927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture to right LI4 and LI11 (ITO, EX-160)
Description: Electroacupuncture at 2Hz, 0.4m/sec pulse duration
Study NCT01564927 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electroacupuncture to knee caps
Description: Electroacupuncture at 2Hz, 0.4m/sec pulse duration
Study NCT01564927 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture to LI4 and LI11
Description: Electroacupuncture at 2Hz, 0.4m/sec pulse duration
Study NCT04002310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754132
Description: One single injection
Study NCT04647955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.
Study NCT04647955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were treated for 8 weeks.
Study NCT02205684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer game skills training
Description: Playing Nintendo Wii Sports
Study NCT02205684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Aerobic High Intensity Training (HIT)
Study NCT02324270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac epolamine
Description: Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
Study NCT02324270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine
Description: Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
Study NCT02324270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
Study NCT03858959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: topical agent
Description: HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe.
Study NCT02482038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: neuromuscular electrostimulator
Study NCT02586441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
Study NCT02586441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: intravenous 1% propofol (1.5-2.5 mg/kg)
Study NCT02586441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: intravenous rocuronium bromide (0.6 mg/kg)
Study NCT03303664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPROVE Protocol
Description: Comprehensive pain management protocol
Study NCT02192333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive survivorship care
Study NCT02192333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02192333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02192333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone-based booster intervention
Study NCT01057641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spacer
Description: Implantation of a percutaneously implanted interspinous device (spacer)
Study NCT01057641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy
Description: physiotherapy
Study NCT00945295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A, BoNT-A
Description: Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
Study NCT00945295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Therapy
Description: Rehabilitation therapy
Study NCT00335179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara (imiquimod 5% cream)
Description: Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
Study NCT00335179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream in 250 mg
Study NCT03133884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
Study NCT03133884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: superficial acupuncture
Description: The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
Study NCT03300102 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, interviews and or tissue donation
Description: Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
Study NCT04408378 — intervention group
Intervention type: OTHER
Intervention: observation of covid 19 pneumonia
Description: We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
Study NCT03858959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: topical agent
Description: HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe.
Study NCT01952587 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A peripheral blood sample
Description: A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
Study NCT02812498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
Study NCT02812498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Description: Group of patients followed in a traditional way
Study NCT02249897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOLESTYRAMINE
Description: CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
Study NCT02249897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHOLESTYRAMINE
Description: CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
Study NCT03472846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia, 60 Mg/mL Subcutaneous Solution
Description: antiresorptive treatment with Prolia
Study NCT03472846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: osteoanabolic treatment with Forsteo
Study NCT01078818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV trivalent saccharose hydroxide ferrous
Description: Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h
Study NCT01078818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ferrous fumarate
Description: 200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet
Study NCT01078818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral and intravenous Placebo
Description: Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
Study NCT03506230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: A bonus to buy their medications if they reduce their HBA1c
Study NCT05160142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DICE
Description: 10-week culinary and nutrition education program for children with type I diabetes
Study NCT00875693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
Study NCT01412489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYALOBARRIER Gel
Description: For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
Study NCT01208753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555
Description: two different aqueous formulations
Study NCT01208753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 aqueous
Description: multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
Study NCT01208753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Study NCT00579384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26489112
Description: Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
Study NCT00579384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
Study NCT00450125 — intervention group
Intervention type: OTHER
Intervention: Six-Minute Walk Test
Description: Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
Study NCT00450125 — intervention group
Intervention type: OTHER
Intervention: Exercise stress test
Description: Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
Study NCT02366091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
Study NCT02366091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
Study NCT02366091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
Study NCT04636216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE parent training
Description: Weekly 1.5 hour parent training meetings for eight weeks
Study NCT03595618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Film-coated tablets of GLPG1972 for oral use.
Study NCT03595618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablets of matching placebo for oral use.
Study NCT04041856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Ophthalmic
Description: Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Study NCT03607279 — intervention group
Intervention type: PROCEDURE
Intervention: NGAL
Study NCT03595618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets of matching placebo for oral use.
Study NCT02256397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard comprehensive care
Description: Standard comprehensive care at High Risk Children's Clinic
Study NCT02256397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard comprehensive care
Description: Standard comprehensive care at High Risk Children's Clinic
Study NCT02256397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced comprehensive care
Description: standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller~* 5 and above--> will receive home-centered comprehensive care with propeller and PIKO
Study NCT00042471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Description: Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
Study NCT04277806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Oral feeding process
Description: From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
Study NCT03338322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisted file adaptive
Description: Endodontic files that are used in preparation of root canals with adaptive motion
Study NCT03338322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciproc
Description: Endodontic files that are used in root canal preparation with reciprocation motion
Study NCT03554343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: test for SMN1 exon 7 deletion
Description: Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
Study NCT02895126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appui Parental program
Study NCT02895126 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular parental support
Study NCT01105065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine 0.15%
Description: One drop in each eye three times a day for 8 weeks.